POLR1D
Basic information
Region (hg38): 13:27620742-27744237
Links
Phenotypes
GenCC
Source:
- Treacher Collins syndrome 2 (Definitive), mode of inheritance: AD
- Treacher Collins syndrome 2 (Strong), mode of inheritance: AD
- Treacher-Collins syndrome (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Treacher Collins syndrome 2 | AD/AR | Audiologic/Otolaryngologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Audiologic/Otolaryngologic; Craniofacial; Dental | 21131976; 24603435; 25790162 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the POLR1D gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | |||||
missense | 25 | 27 | ||||
nonsense | 3 | |||||
start loss | 0 | |||||
frameshift | 7 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 15 | 24 | ||||
Total | 2 | 7 | 27 | 13 | 22 |
Variants in POLR1D
This is a list of pathogenic ClinVar variants found in the POLR1D region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
13-27621695-C-T | Benign (Dec 12, 2018) | |||
13-27621752-G-A | Benign (Dec 12, 2018) | |||
13-27621835-C-T | Benign (Oct 16, 2018) | |||
13-27621874-C-A | Benign (Oct 16, 2018) | |||
13-27621877-C-T | Benign (Apr 04, 2019) | |||
13-27621896-G-C | Benign (Dec 10, 2018) | |||
13-27622027-G-A | Benign (Dec 06, 2023) | |||
13-27622067-G-T | Benign (Dec 17, 2018) | |||
13-27622184-A-G | Benign (Nov 29, 2018) | |||
13-27622261-G-A | Benign (Jan 02, 2019) | |||
13-27622682-G-C | Likely benign (Feb 16, 2019) | |||
13-27622695-G-A | Benign (Dec 17, 2018) | |||
13-27622698-A-T | Likely benign (Dec 12, 2018) | |||
13-27622856-A-G | Likely benign (Jul 03, 2023) | |||
13-27622867-G-A | Likely benign (Aug 27, 2023) | |||
13-27622904-C-T | Uncertain significance (Apr 26, 2019) | |||
13-27622906-G-GA | Treacher Collins syndrome 2 | Likely pathogenic (Feb 23, 2023) | ||
13-27622914-G-A | POLR1D-related disorder | Likely benign (Mar 01, 2019) | ||
13-27622935-G-GGT | Treacher Collins syndrome 2 | Pathogenic (Jan 01, 2011) | ||
13-27622936-GTCCAGGCAGCTGGAACAGATAGACACTGT-G | Treacher Collins syndrome 2 | Likely pathogenic (Sep 01, 2022) | ||
13-27622945-G-C | Inborn genetic diseases | Uncertain significance (Oct 03, 2022) | ||
13-27622945-GCTGGAACAGATAGACACTGTGTGACATTTGTATTGCACGAGGAAGA-G | Likely pathogenic (Dec 21, 2023) | |||
13-27622952-C-T | Uncertain significance (Dec 13, 2023) | |||
13-27622956-T-TA | Pathogenic (Jan 16, 2022) | |||
13-27622973-T-A | Inborn genetic diseases | Uncertain significance (Apr 20, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
POLR1D | protein_coding | protein_coding | ENST00000302979 | 2 | 46646 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.364 | 0.591 | 125744 | 0 | 1 | 125745 | 0.00000398 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.169 | 70 | 74.1 | 0.945 | 0.00000396 | 880 |
Missense in Polyphen | 15 | 19.166 | 0.78263 | 252 | ||
Synonymous | 0.987 | 21 | 27.6 | 0.761 | 0.00000153 | 245 |
Loss of Function | 1.57 | 1 | 4.66 | 0.214 | 2.62e-7 | 58 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);Cytosolic DNA-sensing pathway - Homo sapiens (human);RNA polymerase - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);Pyrimidine metabolism;Eukaryotic Transcription Initiation;B-WICH complex positively regulates rRNA expression;Positive epigenetic regulation of rRNA expression;NoRC negatively regulates rRNA expression;Negative epigenetic regulation of rRNA expression;Epigenetic regulation of gene expression;Gene expression (Transcription);tumor suppressor arf inhibits ribosomal biogenesis;RNA Polymerase I Promoter Clearance;Purine metabolism;RNA Polymerase I Transcription Termination;RNA Polymerase I Transcription;RNA Polymerase I Transcription Initiation;RNA Polymerase I Promoter Escape;Pyrimidine metabolism;RNA Polymerase I Chain Elongation;RNA Polymerase III Transcription Termination;RNA Polymerase III Chain Elongation;TNFalpha;RNA Polymerase III Abortive And Retractive Initiation;RNA Polymerase III Transcription Initiation From Type 1 Promoter;RNA Polymerase III Transcription Initiation From Type 2 Promoter;RNA Polymerase III Transcription Initiation From Type 3 Promoter;RNA Polymerase III Transcription Initiation;RNA Polymerase III Transcription
(Consensus)
Recessive Scores
- pRec
- 0.163
Intolerance Scores
- loftool
- 0.245
- rvis_EVS
- -0.32
- rvis_percentile_EVS
- 31.69
Haploinsufficiency Scores
- pHI
- 0.206
- hipred
- Y
- hipred_score
- 0.778
- ghis
- 0.535
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.909
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Polr1d
- Phenotype
Zebrafish Information Network
- Gene name
- polr1d
- Affected structure
- neuroepithelial cell
- Phenotype tag
- abnormal
- Phenotype quality
- apoptotic
Gene ontology
- Biological process
- transcription, DNA-templated
- Cellular component
- RNA polymerase III complex;RNA polymerase I complex
- Molecular function
- RNA polymerase I activity;RNA polymerase III activity;DNA binding;DNA-directed 5'-3' RNA polymerase activity;protein binding;protein dimerization activity